FDA Grants Priority Review to Tafasitamab/Lenalidomide Combination for DLBCL

The FDA granted priority review to a biologics license application for tafasitamab in combination with lenalidomide for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.

Source: CancerNetwork - March 2, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news